Absstract of: WO2023039954A1

An Alzheimer's disease biomarker and an application thereof. The Alzheimer's disease biomarker is asparagine. It is first detected that the level of asparagine in an Alzheimer's disease blood sample is significantly lower than that of a normal blood sample, and asparagine in blood is used as an Alzheimer's disease biomarker. By detecting the level of asparagine in blood, the early diagnosis of Alzheimer's disease can be assisted, thereby facilitating non-invasive and rapid detection, and the characteristics of timeliness, convenience, high specificity and high sensitivity are provided.

Absstract of: US2023087041A1

Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

Absstract of: US2023088509A1

This disclosure relates to compositions and methods of diagnosing neurodegenerative disease by analyzing protein expression profiles in a subject.

Absstract of: WO2023040092A1

Disclosed are an S-methyl-5'-thioadenosine biomarker for Alzheimer's disease, and the use thereof. The biomarker for Alzheimer's disease is S-methyl-5'-thioadenosine. It has been detected for the first time that the level of S-methyl-5'-thioadenosine in a fecal sample of someone with Alzheimer's disease is significantly lower than that in a normal fecal sample. S-methyl-5'-thioadenosine in feces is used as a biomarker for Alzheimer's disease, and the early diagnosis of Alzheimer's disease can be assisted by means of detecting the level of S-methyl -5'-thioadenosine in feces. Therefore, the biomarker facilitates non-invasive rapid detection, and has the characteristics of timeliness, convenience, high specificity and high sensitivity.

Absstract of: WO2021228125A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

Absstract of: EP4151747A1

The present invention provides a method and system for diagnosing a central nervous system disease, and a composition, and a kit. The diagnosing system comprises: a first detection module, used for detecting a central nervous system-derived marker in a biological body fluid of a subject; a second detection module, used for detecting a central nervous system disease-related marker in the biological body fluid of the subject; and a diagnosis module, diagnosing, on the basis of central nervous system-derived marker and central nervous system disease-related marker detection results respectively obtained by the first detection module and the second detection module, whether the subject suffers from a central nervous system disease.

Absstract of: WO2023038071A1

The present invention relates to providing a method for easily detecting Alzheimer's disease (AD) and a method for easily stratifying AD pathology phases, as well as providing a reagent with that can be used in these methods. The present invention provides a method for easily detecting Alzheimer's disease (AD) and a method for easily stratifying AD pathology phases due to measurement of extracellular-secretion-vesicle-containing proteins making it possible to detect AD and stratify AD pathology phases, and a reagent that can be used in these methods.

Absstract of: WO2023038876A1

The disclosure provides quinoline and quinazoline derivative compounds and pharmaceutical compositions thereof. These compounds inhibit the interactions between GAG- binding amyloid peptides (GBAPs) and heparan sulfate glycosaminoglycans (HS-GAGs) and thus may be useful as therapeutics for the treatment and prevention of neurodegenerative diseases associated with amyloidosis, for example Alzheimer's Disease, and for other amyloid disorders. The present disclosure further provides methods of treatment and prevention of neurodegenerative and amyloid diseases, and methods for identifying small organic molecule compounds that can inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding amyloid peptides (GBAPs).

Absstract of: US2023081393A1

The present invention is the protein of lactoferrin, or an encoding nucleic acid of the same, for use in the diagnosis or prognosis of Alzheimer's disease (AD). The invention is a method of diagnosis or prognosis of AD in a subject, comprising assessing the level of lactoferrin in the saliva or in a saliva sample of said subject and determining whether said level is above or below a value of 7.43 μg/ml, wherein a value below 7.43 μg/ml is indicative of AD or of the prognosis of AD. Another aspect is the protein of lactoferrin, or an encoding nucleic acid of the same, for use in the diagnosis of Parkinson's disease (PD) in a saliva sample of a subject.

Absstract of: WO2023035300A1

An Alzheimer's disease biomarker, and a screening method therefor and an application thereof. The Alzheimer's disease biomarker is 11(Z),14(Z)-eicosadienoic acid. The screening method for the Alzheimer's disease biomarker comprises: acquiring samples, testing the samples, and performing structural identification and data analysis on metabolites in the samples, wherein specifically, metabolites in faeces samples can be tested by liquid chromatography-mass spectrometry, to carry out structural identification on the metabolites; and selecting a metabolite showing a difference from the metabolite level of a control group as the Alzheimer's disease biomarker. Using 11(Z),14(Z)-eicosadienoic acid as an Alzheimer's disease biomarker is of great significance to clinical early diagnosis of Alzheimer's disease; the present invention can be used for preparing a diagnostic tool for Alzheimer's disease, predicting the individual treatment effects of patients with Alzheimer's disease, and preparing drugs for treating Alzheimer's disease.

Absstract of: WO2023035465A1

Disclosed are taurine as a biomarker for Alzheimer's disease and the use thereof. The biomarker for Alzheimer's disease is taurine. It is detected for the first time that the level of taurine in a stool sample of a patient with Alzheimer's disease is significantly higher than that in a stool sample of a normal person. Taurine in the stool is used as the biomarker for Alzheimer's disease, and the early diagnosis of Alzheimer's disease can be assisted by means of detecting the level of taurine in the feces, which facilitates non-invasive rapid detection, and has the characteristics of timeliness, convenience, high specificity and high sensitivity.

Absstract of: WO2023035467A1

A biomarker for Alzheimer's disease and the use thereof. The biomarker for Alzheimer's disease is inosine. It is detected for the first time that the level of inosine in a stool sample of a patient with Alzheimer's disease is significantly lower than that in a stool sample of a normal person. Inosine in the stool serves as the biomarker for Alzheimer's disease, and the early diagnosis of Alzheimer's disease can be assisted by detecting the level of inosine in the stool, which facilitates non-invasive and rapid detection, and has the characteristics of timeliness, convenience, high specificity and high sensitivity.

Absstract of: WO2023037109A1

The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.

Absstract of: WO2023039107A2

Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

Absstract of: WO2016005328A2

The invention relates to immunogenic products based on muteinamyloid β(Aβ) amino acid sequences, in particular to oligomers of Aβ muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.

Absstract of: US2014018341A1

A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

Absstract of: US2018193325A1

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Absstract of: WO2021142163A1

The present invention provides compositions and methods using certain GPR4-regulated genes and expression products thereof (namely YAP1, CTGF, CCND3, BDNF, VCL, ITGB3) for diagnosis, treatment and prevention of Alzheimer's disease and Mild Cognitive Impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or Mild Cognitive Impairment based on the differential expression of GPR4-regulated genes.

Absstract of: AU2021309020A1

A method for detecting p217+tau in blood-based samples from a subject with high sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the assay.

Absstract of: US2023076840A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

Absstract of: US2023075190A1

The present invention is directed to compositions, kits, and methods for the treatment of conditions associated with hyperproliferative cellular division, such as cancer, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, conditions associated with the immune deficiency disease or disorder, Alzheimer's disease and conditions associated with Alzheimer's disease, and/or an autoimmune disease and conditions associated with autoimmune diseases. One aspect provides a composition extracted from a biological fluid, such as plasma, from an animal inoculated with an antigenic agent, such as an Ascomyceta (e.g., Aspergillus). One aspect provides for a method of producing such composition. One aspect provides a method for treating conditions associated with hyperproliferative cellular division, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, or conditions associated with immune deficiency disease or disorder, Alzheimer's disease or conditions associated with Alzheimer's disease, or an autoimmune disease or conditions associated with autoimmune diseases, by administering such a composition to a subject in need thereof.

Absstract of: US2023069905A1

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

Absstract of: WO2023034096A1

Compositions and methods are provided for classification and prognosis of susceptibility to development of Alzheimer's disease (AD). Surprisingly it is shown that individuals with clonal hematopoiesis of indeterminate potential (CHIP) have reduced risk of AD dementia or AD-related pathology. In an individual, the same CHIP-associated mutations found in circulating hematopoietic cells can also be detected in microglia cells of the brain; suggesting a role for mutant, marrow-derived cells in attenuating risk of AD.

Absstract of: US2023071480A1

In an ex vivo method of diagnosing a disease associated with synaptic degeneration, a concentration of beta-synuclein in a cerebrospinal fluid (CSF) sample taken from a patient is determined by an enzyme-linked immunosorbent assay (ELISA).

Absstract of: KR20230033887A

본 발명은 알츠하이머병의 조기 진단을 위한 정보제공 방법에 관한 것으로, 구체적으로 본 발명은 대뇌의 내측 전전두피질(mPFC; medial prefrontal cortex)에서의 아밀로이드 침착 여부 또는 미토콘드리아가 결핍된 시냅스 밀도를 분석하는 단계를 포함하는 알츠하이머병의 조기 진단을 위한 정보제공방법에 관한 것이다. 본 발명은 알츠하이머병이 발병하게 되면 뇌의 V1 영역이 아닌 mPFC 영역 특이적으로 아밀로이드 축적이 증가하고, 특히 mPFC의 층 2(layer 2)에서 흥분성 시냅스 밀도가 감소되며, 시냅스 전 미토콘드리아가 결핍된 시냅스와 미토콘드리아 결핍 축삭말단과 접촉하는 얇은형 가시의 밀도가 선택적으로 감소될 뿐만 아니라, 축삭말단 당 미토콘드리아 수와 다중 미토콘드리아를 함유하는 축삭말단의 수가 감소된다는 것을 규명하였다. 따라서 본 발명은 알츠하이머병 발병 시 뇌 영역 특이적으로 발생하는 상기와 같은 현상을 확인함으로써 알츠하이머병을 조기에 진단할 수 있는 새로운 방법을 제공하는 효과를 갖는다.